Latest News & Updates
Breaking News
4 hours ago
Vaibhavi M.
Other trending news you may like to read
FDA Approves GSK’s Lynavoy As First US Therapy For Cholestatic Pruritus In Primary Biliary Cholangitis
FDA approves GSK's Lynavoy (linerixibat) as the first U.S. therapy for cholestatic pruritus in primary biliary cholangitis, with Phase III GLISTEN data showing relief within two weeks.
Vaibhavi M.
Rhythm Pharma’s IMCIVREE® Secures FDA Approval For Acquired Hypothalamic Obesity After Strong Phase III BMI Reduction Data
FDA approves IMCIVREE® (setmelanotide) as the first therapy for acquired hypothalamic obesity in adults and children 4+, with 18.4% placebo-adjusted BMI reduction in Phase III.
Vaibhavi M.
FDA Approves Novo Nordisk’s Wegovy® HD For Long-Term Weight Management, Delivers Up To 20.7% Weight Loss; US Launch Planned For April 2026
FDA approves Novo Nordisk's Wegovy® HD, a once-weekly semaglutide 7.2mg injection for chronic weight management, delivering 20.7% mean weight loss; U.S. launch planned for April 2026.
Vaibhavi M.
Pfizer’s TALZENNA–XTANDI Combo Shows Strong Phase III Results In HRR-Mutated Metastatic Prostate Cancer, With Significant Progression-Free Survival Benefit
Pfizer's Phase III TALAPRO-3 trial shows TALZENNA plus XTANDI significantly improves progression-free survival in HRR gene–mutated metastatic castration-sensitive prostate cancer versus XTANDI alone.
Vaibhavi M.
